A 600mg of fixed‐dose linezolid in renally impaired patients versus 15mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus

ObjectivesBoth linezolid and vancomycin are approved by USFDA and IDSA guidelines for the management of nosocomial pneumonia due to methicillin‐resistant Staphylococcus aureus (MRSA) in clinical practice. Baseline creatinine clearance is the criterion for prescribing vancomycin or linezolid for hosp...

Full description

Saved in:
Bibliographic Details
Published in:Tropical medicine & international health 2023-04, Vol.28 (4), p.315-323
Main Authors: Wang, Mengqin, Liu, Xiao, Tian, Zhaoxing
Format: Article
Language:English
Subjects:
Bacteremia
Creatinine
Drug resistance
Impairment
Linezolid
Methicillin
Nosocomial infection
Parameters
Patients
Pneumonia
Renal function
Staphylococcus aureus
Staphylococcus infections
Steroid hormones
Vancomycin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesBoth linezolid and vancomycin are approved by USFDA and IDSA guidelines for the management of nosocomial pneumonia due to methicillin‐resistant Staphylococcus aureus (MRSA) in clinical practice. Baseline creatinine clearance is the criterion for prescribing vancomycin or linezolid for hospital‐acquired pneumonia in our institution. However, patients with renal function impairment are far more difficult to manage in intensive care. Thus, the objectives of the study were to compare the clinical efficacy and safety of 600 mg of fixed‐dose linezolid with intermittent dose‐optimised vancomycin in hospital‐acquired pneumonia due to MRSA and to evaluate parameters of clinical cure.MethodsAnalysis of a review of patients' charts. Patients with creatinine clearance
ISSN:1360-2276
1365-3156
DOI:10.1111/tmi.13866